Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists

2004 ◽  
Vol 19 (6) ◽  
pp. 656-662 ◽  
Author(s):  
Judit Horvath ◽  
Robin D. Fross ◽  
Galit Kleiner-Fisman ◽  
René Lerch ◽  
Hans Stalder ◽  
...  
Keyword(s):  
Heart Disease ◽  
Dopamine Agonists ◽  
Ergot Derivative

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

2006 ◽  
Vol 21 (8) ◽  
pp. 1261-1264 ◽  
Author(s):  
Ji-Youn Kim ◽  
Eun Joo Chung ◽  
Seung Woo Park ◽  
Won Yong Lee
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Heart Disease ◽  
Valvular Heart Disease ◽  
Dopamine Agonists ◽  
Ergot Derivative

New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance

2004 ◽  
Vol 19 (6) ◽  
pp. 611-613 ◽  
Author(s):  
Olivier Rascol ◽  
Atul Pathak ◽  
Haleh Bagheri ◽  
Jean-Louis Montastruc
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Dopamine Agonists ◽  
Old Drugs ◽  
Ergot Derivative

Cardiopulmonary Complications of Ergot-Derivative Dopamine Agonists

2004 ◽  
Vol 65 (10) ◽  
pp. 1429-1430 ◽  
Author(s):  
Michael J. Rack ◽  
Alp Sinan Baran ◽  
Allen C. Richert ◽  
Howard P. Roffwarg
Keyword(s):  
Dopamine Agonists ◽  
Cardiopulmonary Complications ◽  
Ergot Derivative

scholarly journals Update on Dopamine Agonists in Parkinson's Disease: “Beyond Bromocriptine”

1987 ◽  
Vol 14 (S3) ◽  
pp. 474-482 ◽  
Author(s):  
Anthony E. Lang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Dopamine Agonists ◽  
Infusion Therapy ◽  
Foreseeable Future ◽  
Phase 3 ◽  
Beneficial Effects ◽  
Elderly Humans ◽  
Ergot Derivative

ABSTRACT:Since the initiation of bromocriptine therapy for Parkinson's disease several newer dopamine agonists have been developed. Pergolide has reached the stage of Phase 3 clinical trials and will probably be available for general use sometime in the foreseeable future. Lisuride shows most promise in its parenteral form for infusion therapy of patients with severe fluctuations. Mesulergine, another ergot-derivative and ciladopa, a new non-ergot agonist, have been withdrawn from further clinical use due to tumorogenesis in rats. It is questionable how applicable these findings are to the use of the drugs in elderly humans with parkinsonism. Recently a small number of drugs have been found to have postsynaptic dopamine agonist properties only in the setting of denervated supersensitive dopamine receptors. These agents may be particularly effective in the early treatment of patients with Parkinson's disease. This paper will review a number of the dopamine agonists which have been developed since the introduction of bromocriptine therapy. Several of these have shown beneficial effects in early clinical trials while others show promise in preclinical studies of animal models of parkinsonism.

Sign in / Sign up

Export Citation Format

Share Document